Abion Executives Continue Company Stock Purchases, "Strengthening Responsible Management"

Shin Younggi, CEO of Abion, purchased an additional 100,000 shares of the company’s stock earlier this month, following last month’s acquisition of approximately 720,000 shares.

According to Abion on August 12, this latest stock purchase was made as the company pursues both business and financial restructuring, as well as the global commercialization of its core pipeline. The company explained that this demonstrates its confidence in long-term growth potential and its commitment to responsible management. Vice President Woo Sungyun and Vice President Jang Giryong also increased their holdings earlier this month with acquisitions of 100,000 shares and 35,000 shares respectively, indicating that key executives continue to expand their equity stakes.

Uncertainties surrounding the business are also being resolved. Abion recently reached a settlement in a patent and legal dispute over the use of genetic information with India’s Ocimum. As a result, the company has secured a foundation to focus on the development and commercialization of its core new drug pipeline and platform technology. Abion has also obtained a U.S. patent for the core proprietary technology of its self-developed immuno-oncology platform, “Interferon Beta Antibody Conjugate (iRAC™).” Building on this U.S. patent, the company plans to promote joint development, technology transfer, and the expansion of strategic partnerships with global pharmaceutical companies.

CEO Shin stated, “The continued purchase of company shares by key executives demonstrates our commitment to maximizing long-term growth potential and corporate value,” adding, “Having resolved the legal uncertainty surrounding our patents and secured the U.S. patent for iRAC™ core proprietary technology, we will accelerate global commercialization of our core pipeline.”

This content was produced with the assistance of AI translation services.